Changes in Hong Kong stocks | Kangfang Biotech (09926) rose more than 3% in early trading. The updated data of EVO's first-line treatment TNBC was released in ESMO IO 2025

The Zhitong Finance App learned that Kang Fang Biotech (09926) rose more than 3% in early trading. As of press release, it had risen 2.83% to HK$120.2, with a turnover of HK$100 million.

According to news, on December 11, according to Kang Fang Biotech's official WeChat account, at the 2025 European Society of Oncology Immuno-Oncology Conference (ESMO IO) held in London, England, Kang Fang Bioupdate released the PD-1/VEGF bispecific antibody developed independently by the company and first-line chemotherapy in first-line treatment of locally advanced unresectable or metastatic triple-negative breast cancer (TNBC) phase II clinical study, showing the huge clinical potential of the EVO solution in the first-line treatment of TNBC.

Previously, based on excellent efficacy and safety, the first-line treatment of TNBC with evossi combination therapy was included in the list of breakthrough therapeutic agents (BTD) by the Drug Evaluation Center (CDE) of the China Drug Administration (CDE). Currently, the multicenter, randomized, double-blind phase III clinical study (Harmoni-BC1/AK112-308) of this indication is being carried out efficiently.

According to reports, evosimab is the world's first PD-1/VEGF bispecific tumor immunotherapy drug independently developed by Kangfang Biotech. The first indication for evosimab was approved for marketing by the China National Drug Administration in May 2024 for locally advanced or metastatic NSQ-nsCLC in the progression of EGFR-TKI treatment. Evosil became the world's first new bispecific antibody with a “tumor immunity+antiangiogenesis” collaborative anti-tumor mechanism to be approved for marketing. In November of the same year, evosimab was included in the national health insurance catalogue.